41 results about "Trichostatin A" patented technology

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.

This invention pertains to the development of a screening system to identify (screen for) HER2 promoter silencing agents. Such agents are expected to be of therapeutic value in the treatment of cancers characterized by HER2 amplification/upregulation. In addition, this invention pertains to the discovery that histone deacetylase (HDAC) inhibitors like sodium butyrate and trichostatin A (TSA), in a time and dose dependent fashion can silence gnomical.ly integrated and/or amplified/overexpressing promoters, such as that driving the HER2/ErbB2/neu oncogene, resulting in inhibition of gene products including transcripts and protein, and subsequent production of tumor/cell growth inhibition, apoptosis and/or differentiation. In another embodiment, this invention provides novel SNPs associated with the coding region of the ErbB2. proto-oncogene. The SNPs are indicators for altered risk, for developing ErbB2-positive cancer in a mammal

The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like)

A switch to haploid embryogenesis is controlled by the activity of histone deacetylases (HDACs). Blocking HDAC activity with HDAC inhibitors (HDACi), e.g. trichostatin A (TSA), in Brassica napus, B. rapa, B. oleracea, Arabidopsis thaliana and Capsicum annuum male gametophytes leads to a large increase in the proportion of cells that undergo embryogenic growth. In B. napus, treatment with one specific HDACi (SAHA) improves the conversion (i.e. germination) of these embryos into seedlings. Existing methods of culturing microspores of angiosperm plants following stress to produce haploid embryos, haploid plants and double haploid plants can be improved by adding HDACi to the culture medium. Advantageously, species hitherto recalcitrant to haploid embryogenesis via microspore culture are rendered useful when using HDACi. Haploid and double haploid plants are of industrial application in the plant breeding programmes.

Chiral synthesis of Trichostatin A has better intermediate stability and more product yield. It's simple and cheap.

The invention provides a method for regulating fermentation microorganisms through epigenetic modification. By the addition of a histone deacetylase inhibitor TSA (trichostatin A), epigenetic modification fermentation regulating is conducted. The method has the advantages that according to the fermentation microorganisms regulated through epigenetic modification, because silent gene expression is activated, the inhibitory activity of a metabolite to vibrio anguillarum is remarkably improved, and secondary metabolites are obviously enriched.

The invention provides a culture method for in-vitro human oocyte preantral follicles. The culture method is characterized by comprising the following specific steps of: 1) unfreezing the in-vitro human oocytes placed in frozen protecting solution containing cane sugar and propylene glycol and subjected to liquid nitrogen low-temperature storage, and then reviving and culturing; and 2) separating and extracting the in-vitro human oocytes obtained by reviving and culturing, then placing the in-vitro human oocytes in nutrient solution containing follicle-stimulating hormone (FSH), and performing preantral culture, wherein the culture for in-vitro human oocyte preantral follicles needs the support of FSH, and FSH can be used for promoting the growth of the follicles, increasing the survival time of the follicles, promoting the proliferation of granular cells, and promoting the maturation of the oocytes, as well as is an important factor for regulating and controlling the growth and development of the follicles; and trichostatin A can be used for effectively inhibiting the proliferation of tumour cells, regulating and controlling the progress of a cell cycle and then inducing the apoptosis of tumour cells, thus ensuring the survival quality of the cells. The method has important significance on researches in the aspect of test-tube babies.

The invention relates to application of a histone deacetylase inhibitor compound in preparing a medicament for treating and/or preventing atherosclerosis by strengthening a reverse cholesterol transport mechanism, wherein a histone deacetylase inhibitor is trichostatin A shown in a formula 1 or suberoylanilide hydroxamic acid shown in a formula 2.

The invention relates to the technical field of medicines, especially relates to an application of deacetylase inhibitors in preparation of medicaments for promoting insulin secretion, and wherein the deacetylase inhibitor is nicotinamide (NAM) or trichostatin A (TSA). The rat islet cells are co-incubated with the deacetylase inhibitor NAM for 1 h, and insulin secretion stimulated by glucose is improved by about 50%; by using the deacetylase inhibitor TSA to treat islet cells for 12 h while the glucose concentration is 3.3 mmol/L, insulin secretion can be improved, and insulin secretion is improved obviously after 16 h; and insulin secretion is mildly up-regulated after islet cells are treated by NAM for 16 h. Therefore, the inhibitors NAM and TSA are applicable to preparation of the medicaments for promoting insulin secretion, and the medicaments will have good treatment effect in diabetes treatment. Also, more scientific bases are provided for more reasonable clinic use of the deacetylase inhibitors NAM and TSA.

By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A)-mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect), it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.

A method of promoting napa cabbage microspore embryogeny and direct production of plantlets is provided to overcome the problem that microspore culturing techniques at present are low in microspore embryogeny rate, low in the rate of direct production of plantlets and long in culturing period. Through adding a histone deacetylase inhibitor-trichostatin A (TSA) into an induction medium, the microspore embryogeny rate and the rate of direct production of plantlets of napa cabbage are increased. In an NLN induction medium to which 0.025-0.10 muM of the TSA is added, the microspore embryogeny rate of the napa cabbage is increased by 1.46-2.48 times, and the rate of direct production of plantlets of the napa cabbage is increased by 1.12-1.39 times. The medium is a liquid mixture consisting of the NLN induction medium, the 0.025-0.10 muM of the TSA, 130 g.L<-1> of cane sugar, 100 muL of sterilized agarose having a concentration of 0.5 g.L<-1> and 10 g.L<-1> of activated carbon.